KAEL-GemVax reports significant interim progress in UK TeloVac Phase III study of GV1001 anti-telomerase vaccine in pancreatic cancer

* Recruitment 70% complete for only vaccine in Phase III targeting pancreatic
cancer
* Breakthrough potential as “universal” therapeutic cancer vaccine

OSLO, Norway–(Business Wire)–
KAEL-GemVax, a leading oncology vaccine company, today announced, through its
subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III
TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in
pancreatic cancer. The company also strongly believes GV1001 has major
“blockbuster” potential as a universal therapeutic cancer vaccine and is
developing a strong pipeline for other indications, including lung and liver
cancer and melanoma.

The largest cancer vaccine therapy trial ever in the UK, currently funded by
Cancer Research UK, the TeloVac study is being run by the Liverpool Cancer
Trials Unit. KAEL-GemVax has just received the second interim report noting that
the number of patients recruited reached 755 out of 1110 in 52 centres in the UK
in June. This means recruitment is now almost 70% complete and remains well on
schedule for LPFV in October 2011 and NDA filing soon after. A recent
Datamonitor report forecasted the market for therapeutic cancer vaccines to
reach $4.7 billion by 2018 in 7 major markets.

Director of the LCTU, Professor John Neoptolemos commented: “GV1001 is the most
advanced therapeutic cancer vaccine currently in development and we are
extremely pleased with the progress of trials so far. Patient recruitment across
our centres continues and we are seeing some good immunological responses.”

The primary trial objective is length of survival. The TeloVac study was
initiated in 2007 after the Phase I/II study showed overall survival of 8.6
months, compared to the 5.6 months of current standard treatment Gemcitabine. It
is a prospective, controlled, multicentre, randomised clinical trial comparing
combination Gemcitabine and Capecitabine therapy with concurrent and sequential
chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic
pancreatic cancer.

KAEL-GemVax CEO Dr Jay Sangjae Kim added: “These results from the independent
Data Monitoring Committee on the TeloVac trial in the UK are extremely
encouraging. Currently pancreatic cancer is one of the most difficult cancers to
treat and there are only a few approved treatments on the market. However, we
believe that the improved overall survival and favourable safety profile that
GVI001 has shown in previous studies creates a strong rationale for providing it
with standard care, and thus creating the first therapeutic vaccine for patients
with pancreatic cancer. In addition, we strongly believe that GV1001 has the
potential to overcome the limits of other current cancer vaccines and become
part of the standard of care not only for pancreatic cancer but for various
other types of cancers. In other words a truly “universal” vaccine will be
available in the near future.”

Corporate Inquiries
KAEL-GemVax
Yena Chung, Global PR Manager
Tel: +82-2 540 6221
Email: yenachung@kaelgemvax.com
or
Media Inquiries
Schwartz Communications
Richard Hayhurst
Tel: +44 (0)7950 878 218
Email: Rhayhurst@schwatrtzcomm.com
or
Schwartz Communications US
Ben Navon
Tel: +1 781-684-0770
Email: Bnavon@schwartzcomm.com

Copyright Business Wire 2010

Cancer news boosts Bristol; Roche, Novartis steady

* Bristol-Myers shares up 2.6 percent in thin German trade

* Melanoma data underpins sales hopes for ipilimumab

* Roche ovarian cancer data seen “solid but not stunning”

* Novartis looks well-placed to fight challenger in CML

* UK biotech Antisoma up 22 percent on hopes for mid-stage drug

Pain Therapeutics to Present at Needham Healthcare Conference

SAN MATEO, Calif., June 4, 2010 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc.
(Nasdaq:PTIE) today announced that management will present at the Needham
Healthcare Conference in New York City on Wednesday, June 9th at 4:00 p.m.
Eastern Time.

The presentation will be webcast live and may be accessed from the home page of
Pain Therapeutics’ website at www.paintrials.com. A replay of the webcast will
continue to be available on the website for up to 90 days.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel
drugs. In addition to REMOXY(R), a unique abuse-resistant controlled-release
oxycodone, the company has three drug candidates in clinical programs, including
a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well
as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for
patients with hemophilia.

CONTACT: Pain Therapeutics, Inc.
Judy Ishida, Administrative Manager
650-645-1924
IR@paintrials.com

Pain Therapeutics to Present at Jefferies Healthcare Conference

SAN MATEO, Calif., June 3, 2010 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc.
(Nasdaq:PTIE) today announced that management will present at the Jefferies
Global Life Sciences Conference in New York City on Tuesday, June 8th at 4:00
p.m. Eastern Time.

The presentation will be webcast live and may be accessed from the home page of
Pain Therapeutics’ website at www.paintrials.com. A replay of the webcast will
continue to be available on the website for up to 90 days.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel
drugs. In addition to REMOXY(R), a unique abuse-resistant controlled-release
oxycodone, the company has three drug candidates in clinical programs, including
a novel radio-labeled monoclonal antibody to treat metastatic melanoma, as well
as PTI-202 and PTI-721. Pain Therapeutics is also working on a new treatment for
patients with hemophilia.

CONTACT: Pain Therapeutics, Inc.
Judy Ishida, Administrative Manager
650-645-1924
IR@paintrials.com

Wrinkles, not skin cancer risk, scare indoor tanners

Washington, May 18 (ANI): Young women were more likely to stay away from indoor tanning if they were warned that the practice could increase their risk of getting leathery, wrinkled skin, than being warned about risk of melanoma, the deadliest form of skin cancer, a study found.

The study found a 75 percent reduction in indoor tanning visits if girls were warned of skin deterioration and turning unattractive.

“They””re not worried about skin cancer, but they are worried about getting wrinkled and being unattractive,” said June Robinson, a professor of dermatology at Northwestern University Feinberg School of Medicine and senior author of the study.

The study examined the best strategy to wean college-age women who are considered addicted or pathological tanners from tanning salons.

“The fear of looking horrible trumped everything else. It was the most persuasive intervention, regardless of why they were going to tan,” said Robinson.

The research showed warning them about the effects on their appearance caused a 35 percent drop in their indoor tanning visits, which were measured at intervals up to six months after the intervention.

Joel Hillhouse, lead author of the paper, noted that some women in the study eventually stopped tanning.

“It was a progressive kind of thing. At first the women said they tried sunless tanning as an alternative, but over time they gave up tanning altogether,” he said.

Between 25 to 40 percent of older adolescent girls visit tanning salons, according to the study””s authors.

The study included 435 college women, ages 18 to 22, who visited tanning salons.

Within this population, researchers focused on women who visited salons up to four times a week – more than what is needed to maintain a tan – and who tanned for psychological reasons, not just for a special event.

These tanners included one group who strongly disliked the natural colour of their skin, which was related to a psychological condition called body dysmorphia.

“They thought their skin was disgusting when it was pale,” said Hillhouse.

The other group, who said tanning made them feel happier and more relaxed, showed symptoms of seasonal affective disorder (SAD) on a diagnostic psychological test.

“They were self medicating their own depression,” said Robinson, noting that lying in a tanning bed produces internal opioids.

The women received a 25-page booklet, authored by Hillhouse, that discussed the effect of tanning on appearance and explained how ultraviolet rays destroy collagen in the skin.

The booklet also offered many alternatives to meet the women””s needs for tanning, such as taking an exercise class for socializing and relaxation or getting a spray-on tan or self-tanning cream application at a spa.

After reading the booklet, the women reported their attitudes and behaviours twice a week in diaries.

The study results surprised researchers.

“The hypothesis was because this was an appearance intervention, it would have less of an effect on the people tanning for mood problems. We found the opposite. The intervention worked just as well for people with seasonal affective disorder as for people who didn””t like their skin color. That means it””s a really good intervention for everyone,” said Hillhouse.

Robinson stressed it was also important to offer women alternatives to tanning salons.

The study has been published in Archives of Dermatology. (ANI)

Scientific breakthrough could offer melanoma cure

London, May 16 (ANI): A long-awaited jab, being hailed as a scientific breakthrough which could offer a cure for cancer, is to be tested on the first British patients within weeks.

According to researchers, it can reverse and even cure melanoma, one of the deadliest forms of the disease, most commonly associated with skin cancer, reports The Daily Express.

Professor Lindy Durrant of Nottingham University, who is heading research into the treatment, said: “This is huge. We could now have a vaccine that can target a tumour and kill it without damage to surrounding healthy tissues or cells.

“In the short term, this could cure some patients with the disease and in the long term the jab could be used to prevent people developing it in the first place.”

Trials will begin at hospitals in Manchester, Nottingham and Newcastle.

Brainchild of vaccine company Scancell, the treatment will be given to patients with advanced skin cancer which has spread to other parts of the body, and also to those in the earlier stages of the disease. (ANI)

Early UVA light exposure ‘doesn’t cause melanoma’

Washington, May 5 (ANI): Scientists from The University of Texas MD Anderson Cancer Center have found that early life exposure to ultraviolet A light does not cause melanoma.

The researchers, therefore, concluded that UVA exposure is unlikely to have contributed to the rise in the incidence of melanoma over the past 30 years

UVA is a carcinogen responsible for squamous cell carcinomas that also causes premature aging of the skin and suppresses the immune system. It”s also possible, the authors note, that long-term chronic exposure to UVA can hasten the progression to malignancy of melanocytes in the skin that are already on the path to becoming melanoma.

Study’s lead author David Mitchell, professor in M. D. Anderson”s Department of Carcinogenesis located at its Science Park – Research Division in Smithville, Texas, and colleagues tested the effects of UVA and ultraviolet B (UVB) light exposure in melanoma-prone fish hybrids that develop the disease spontaneously 15-20 percent of the time without exposure to UV light.

The scientists exposed a hybrid form of the genus Xiphophorus, more commonly known as platyfishes and swordtails, to either UVA or UVB daily between their fifth and 10th day of life. The fish were then scored for melanoma 14 months after exposure.

“We found that UVB exposure induced melanoma in 43 percent of the 194 treated fish, a much higher rate than the 18.5 percent incidence in the control group that received no UV exposure,” Mitchell said.

This was expected because UVB exposure at an early age is a well-established cause of melanoma.

Only 12.4 percent of 282 fish exposed to UVA developed the disease, which is not statistically different from the control group.

The study has been reported in the online early edition of the Proceedings of the National Academy of Sciences. (ANI)

Cancer genes switched off in humans

London, Mar 22 (ANI): For the first time, researchers have used short sequences of RNA that can effectively treat skin cancer in people by silencing specific genes behind tumour production.

Mark Davis from the California Institute of Technology in Pasadena and his colleagues have used the technique, called RNA interference (RNAi), to deliver particles containing such sequences to patients with the skin cancer melanoma.

When analysing biopsies of the tumours after treatment, they found that the particles had inhibited expression of a key gene, called RRM2, needed for the cancer cells to multiply.

The researchers created the particles from two polymers plus a protein that binds to receptors on the surface of cancer cells and pieces of RNA called small-interfering RNA, or siRNA, designed to stop the RRM2 gene from being translated into protein.

The siRNA works by sticking to the messenger RNA (mRNA) that carries the gene”s code to the cell”s protein-making machinery and ensuring that enzymes cut the mRNA at a specific spot.

When the components are mixed together in water, they assemble into particles about 70 nanometres in diameter.

The researchers can then administer the nanoparticles into the bloodstream of patients, where the particles circulate until they encounter ”leaky” blood vessels that supply the tumours with blood.

The particles then pass through the vessels to the tumour, where they bind to the cell and are then absorbed.

Once inside the cell, the nanoparticles fall apart, releasing the siRNA. The other parts of the nanoparticle are so small, they pass out of the body in urine.

“It sneaks in, evades the immune system, delivers the siRNA, and the disassembled components exit out,” Natrue quoted Davis as saying.

When researchers analysed tumour samples from three of the patients who volunteered samples, they found fragments of the mRNA in exactly the length and sequence they would expect from the design of their siRNA.

And in at least one patient, the levels of the protein were lower than they were in samples of the tumours taken before treatment.

They also found that patients who were given higher doses had higher levels of siRNA in their tumours.

“The more we put in, the more ends up where they are supposed to be, in tumour cells,” said Davis.

Davis says that by targeting specific genes he hopes these treatments will not have major side effects.

“My hope is to make tumours melt away while maintaining a high quality of life for the patients. We”re moving another step closer to being able to do that now,” he said.

The study has been published in Nature. (ANI)

Types Of Cancer | Types Of Cancer List | Cancer List | Common Cancer Types | Common Cancer Types List | All Types Of Cancer | All Types Of Cancer List

Types Of Cancer | Types Of Cancer List | Cancer List | Common Cancer Types | Common Cancer Types List | All Types Of Cancer | All Types Of Cancer List

Cancer is a term used for diseases in which abnormal cells divide without control and are able to invade other tissues. Cancer cells can spread to other parts of the body through the blood and lymph systems.

Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start – for example, cancer that begins in the colon is called colon cancer; cancer that begins in basal cells of the skin is called basal cell carcinoma.

Common Cancer Types :

* Bladder Cancer
* Breast Cancer
* Colon and Rectal Cancer
* Endometrial Cancer
* Kidney (Renal Cell) Cancer
* Leukemia
* Lung Cancer
* Melanoma
* Non-Hodgkin Lymphoma
* Pancreatic Cancer
* Prostate Cancer
* Skin Cancer
* Thyroid Cancer

For Information About Cancer Website : http://www.cancer.gov

For More Information About All Cancer Types Website : http://www.cancer.gov/cancertopics/alphalist

Sunshine warnings over skin cancer risk ‘overstated’

London, July 12 (ANI): It’s not sunlight but moles that have the highest role in increasing the risk of skin cancer, say scientists who have claimed that the perils of sunbathing are grossly ‘overstated’.

Scientists have said that sunshine is not the main cause of melanoma, but the number of moles on your skin is the most important factor in the risk of getting this dangerous form of skin cancer.

The findings have re-ignited the debate over whether official health warnings about avoiding the sun are overstated.

The scientists involved in the study maintain that sunshine causes only a small proportion of melanoma cases, but in their opinion health warnings would be more useful if they focused on people who have more than 100 moles, and taught them to check regularly the moles for changes in shape, size or colour.

However, melanoma can be treated, for instance by the early removal of a suspicious mole, but it is the most serious type of skin cancer, as it can spread to other organs in the body.

The cancer can start in an existing mole or on normal-looking skin, and can occur in people who have no moles but have fair skin and freckles.

In a recent study, researchers from Queensland, Australia, Montreal, Canada and Philadelphia, America, led by King’s College London, identified two genes, which dictate how many moles someone will have, and their risk of getting skin cancer.

“The number of moles you have is one of the strongest risk factors for melanoma – stronger than sunshine. This paper shows that we found two important genes that control the number of moles you have. Those genes also give you an extra risk of melanoma,” Times Online quoted Tim Spector, professor of genetic epidemiology at King’s College London, as saying.

Dr Veronique Bataille, a researcher at King’s College, London, and dermatologist at West Hertfordshire NHS Trust, argues that we have overemphasised the risk of sun exposure.

She said: “Let’s keep sunshine in the picture because it does make you age and causes you wrinkles – we have never denied that. But let’s move away from scaring people by saying they are going to die because they go in the sun.”

The study has been published in the current issue of the journal Nature Genetics. (ANI)

New biomarkers of melanoma identified

Washington, June 30 (ANI): Scientists from Yale University have identified new biomarkers that will help develop more effective treatment strategies to fight melanoma, the most serious form of skin cancer.

The research team has mapped chemical modifications of DNA in the melanoma genome that will open new avenues for developing improved therapies.

In addition to mutations to the DNA code that can cause malignancies, epigenetic changes – alterations to the chemical modifications of DNA that regulate genes – are frequent in a number of diseases, including cancer.

If the normal epigenetic patterns that regulate gene expression are disrupted, cellular functions can go awry and lead to disease.

Lead researchers Dr Ruth Halaban and Dr Sherman Weissman of Yale University investigated genome-wide epigenetic changes, termed DNA methylation, in melanoma cells.

“This is of particular importance in melanomas, because a major etiological factor is sun exposure,” Halaban said, explaining that inflammation and reactive oxygen species caused by the sun can produce epigenetic changes and mutations.

Halaban added that because DNA methylation can be reversed, it is an attractive target for cancer therapy.

The team then focused on five genes in particular, three of which had not been implicated in melanoma until now.

In clinical specimens, methylation of these promoters was predominantly detected in advanced-stage tumors, suggesting that these markers will be useful for monitoring tumour progression.

Furthermore, they found that by treating melanoma cells with a drug called decitabine, an inhibitor of DNA methylation, these genes could be reactivated.

Halaban suggests that by combining their method for finding methylation markers with the latest DNA sequencing technologies, researchers will be able to uncover genes where an interaction between genetic mutations and epigenetic changes play a role in the development of melanoma, and perhaps other cancers.

With this information, researchers can devise even more effective strategies to combat the disease.

The study is published in Genome Research. (ANI)

Zebrafish may help explain how skin cancer spreads

Washington, May 26 (ANI): Scientists claim that zebrafish can help explain how aggressive human skin cancer, melanoma, grows and spreads.

The pigmented cells in zebrafish helped scientists tease out how oncogenes that are know to contribute to cancer, influence the formation and regulation of melanoma.

Inside the cell, signals are delivered that direct the cell on whether to divide, migrate or even die. In cancer, cells divide, grow and migrate when they should not, therefore resulting in an aggressive disease that can spread throughout the body.

A key molecule in this signalling pathway is RAS, and mutations in it are known to lead to cancer.

During the study, the University of Manchester in England and the University Hospital Zurich in Switzerland generated several zebrafish with changes in RAS or other RAS-regulated proteins to create a useful model that can be used to study and understand human melanoma.

The tumours created from the pigmented cells of zebrafish, known as melanocytes, are easy to see against their thin, light colored bodies.

The researchers say that these fish may be a useful experimental tool for human disease.

Many of the changes they made caused melanoma in the zebrafish, indicating that zebrafish respond similarly to changes in these signals as do humans.

The study is published in Disease Models and Mechanisms. (ANI)

20pct recession-hit Brits planning sunbed holiday

London, May 11 (ANI): The ongoing recession has forced British people to give up sunny holidays and spend more time under tanning lamps, according to a poll.

Almost a third of people surveyed by YouGov have revealed that they were less likely to go on a sunny summer holiday, and almost 19 pct sunbed users plan to spend more time under tanning lamps.

The charity, which runs an annual SunSmart campaign, has warned of the lifetime skin damage caused by sunbeds.

SunSmart campaign manager Katy Scammell said that the intensity of some UV rays from sunbeds could be up to 15 times higher than that of the midday sun.

Moreover, using a sunbed more than once a month or more could increase the risk of skin cancer by more than half.

“Exposure to these rays increases your risk of melanoma, the most dangerous form of skin cancer,” the Daily Express quoted Scammell as saying.

“Not only do the harmful rays increase your risk of skin cancer, but they also lead to premature ageing and the appearance of lines, wrinkles and coarse, leathery skin,” she added. (ANI)

Intervention proves effective in increasing correct breast self-exams

Washington, April 30 (ANI): In a new study, researchers have found that a brief intervention program boosted the number of women correctly performing breast self- exams by tenfold.

The Kaiser Permanente Center for Health Research study is one of the first to show intervention programs can be effective in increasing breast self-exams.

Researchers said that this program is a model that can be used to encourage patients’ participation in their own health care, and can be modified to educate patients about other self-screening techniques for cancers such as melanoma and testicular cancer.

“Many women avoid breast self-exams because they are worried about doing them correctly; however, our study showed that with a relatively simple intervention, women can learn the proper technique, and once they feel confident they will continue to do their exams.” said Nangel Lindberg, Ph.D., lead author and investigator at the Kaiser Permanente Center for Health Research in Portland, Ore.

“This is an excellent opportunity for women to participate in their own health care. Self-exams allow women to become familiar with their breasts, so they can report any changes to their health care provider,” Lindberg added.

The study, conducted from 1998 through 2001, involved more than 600 women, aged 40 to 70, who had a negative mammogram screening within the last two months.

The women were randomized to a group that received dietary counseling with no mention of BSE, or the study group that received a 30 to 45-minute counseling session in which they watched an educational video, practiced BSE on a silicone model, and discussed possible barriers to doing self- exams.

At one and two months after the session, the women also received follow-up phone calls. Before the intervention about six percent of women in both groups were performing adequate self exams – defined as lasting at least five minutes, occurring every month, and fulfilling specific criteria taught during the counseling sessions.

One year after the program, 59 percent of women in the intervention group were performing adequate self-exams, compared to only 12 percent of women who received dietary counseling.

The study is published in the American Journal of Health Promotion. (ANI)

Topical cream may help treat melanoma sans knife

Washington, April 29 (ANI): Researchers at Saint Louis University have found that a topical cream when used together with surgery may help treat melanoma, potentially helping doctors cut less.

Researchers examined two cases of the most common type of melanoma of the head and neck, lentigo maligna (LM), a type of “melanoma-in- situ”, the earliest stage of melanoma.

This early form, known as LM, precedes the more invasive form, lentigo maligna melanoma (LMM), and the progression of LM to LMM typically occurs after 10 to 15 years. Though surgical removal of LM is most often used to treat the non-invasive form of the cancer, it can have high local recurrence rates.
n two patients who had both LM and LMM, researchers used imiquimod in conjunction with surgery. In both patients, surgery was first done to remove the area of known invasive disease, followed by the topical cream to the outer area of LM.

This approach was chosen with patients who did not want extensive surgery due to the large size of the melanoma on their scalp and face.

Researchers found that imiquimod produced good results for patients when used together with surgery to treat the cancer, potentially helping doctors cut less.

These cases, along with other recent studies, suggest that imiquimod may help to reduce the area needing surgery, manage the LM and hopefully minimize its recurrence.

Researchers hope that topical treatments like imiquimod may be used to lower the seriousness and the cost of treating the disease, as well as limit scars from surgery, and, most importantly, improve patient care.

The study is published in Dermatologic Surgery. (ANI)

Genes raise melanoma risk even in those who tan easily

Washington, Apr 22 (ANI): The traditional risk factors for melanoma may not be as helpful in predicting risk in all people as previously thought, claims a new study.

The research has been presented at the American Association for Cancer Research 100th Annual Meeting 2009.

“Traditionally, a clinician might look at a person with dark hair who did not sunburn easily and classify them as lower risk for melanoma, but that may not be true for all people in the population,” said Peter Kanetsky, Ph.D., M.P.H., assistant professor of epidemiology at the University of Pennsylvania.

Kanetsky and his colleagues have identified that genetic variants in MC1R could help to predict melanoma risk in people who are not usually classified as high risk.

While this link previously has been observed, Kanetsky said it is now time to begin discussing genetic factors as part of the overall melanoma risk model.

For the current study, researchers analyzed 779 patients with melanoma from the Pigmented Lesion Clinic of the University of Pennsylvania and compared them with 325 healthy control patients.

Overall, the presence of certain MC1R variants was associated with a more than two-fold risk of melanoma, but this risk was largely confined to those patients who would not usually be considered to be at elevated risk.

Although those with dark hair are not thought to be at increased risk for melanoma, if they had dark hair and also inherited certain MC1R genetic variants, their risk for melanoma increased 2.4-fold. However, no elevated risk was associated with these same MC1R variants in those with blond or red hair.

MC1R was also associated with increased risk among those with dark eye color (3.2-fold increase), who did not freckle (8-fold increase), who tanned after repeated sun exposure (2.4 fold increase) or who tanned immediately without burning (9.5-fold increase). People with these characteristics are usually thought to be at reduced risk for melanoma.

Kanetsky said a clinical screening test for MC1R is not yet available. (ANI)

Women under 30s warned against cancer caused by ‘Binge Tanning’

London, Apr 8 (ANI): “Binge tanning” and excessive sunbed use have made melanoma, the deadliest form of skin cancer, the most common disease for women in their 20s, cautioned a charity.

A survey of 4,000 people carried out last year has revealed that 340 women in their 20s are annually diagnosed with malignant melanoma, indicating a rate of almost one a day.

The above figure is almost double the number found to have breast cancer in the same age bracket.

The survey also found that one in three women has used a sunbed at some point, and a big 80 percent of them first used one before the age of 35 years.

“Spending time on sunbeds is just as dangerous as staying out too long in sun,” Sky News quoted Caroline Cerny, campaign manager for Cancer Research UK’s SunSmart campaign, as saying.

“Sunbeds don’t offer a safe way to tan. The intensity of UV rays in some sunbeds can be more than 10 times stronger than the midday sun.

“Excessive exposure to UV damages the DNA in skin cells which increases the risk of skin cancer and makes skin age faster.

“But, importantly, if people take care not to burn in the sun and don’t use sunbeds, the majority of malignant melanoma could be prevented,” she added. (ANI)

‘Binge Tanning’ Cancer Warning For Under-30s

'Binge Tanning' Cancer Warning For Under-30s

Skin is at risk if not properly covered in sunscreen

“Binge tanning” and sunbeds have led to the deadliest form of skin cancer becoming the most common disease for women in their 20s, a charity has warned.Every year around 340 women in their 20s are diagnosed with malignant melanoma – a rate of almost one a day.

The figure is almost double the number found to have breast cancer in the same age bracket.

Jenna Gurney, 28, was diagnosed with malignant melanoma when she was 21.

From the age of 16 she used sunbeds twice a week but then discovered a mole on her stomach was growing bigger and becoming flaky.

She had the mole removed but was shocked to discover she had melanoma and needed lymph nodes removed from under her arms. She said: “When I was a teenager my friends and I used sunbeds all the time. It was just so important to have a tan all year round and to top it up for nights out.

“When I used sunbeds I used an intensifier cream instead of any kind of protective sun lotion. On holiday, I did put on sun lotion but never worried about regularly reapplying it or using a high factor.

“Even though the risks were at the back of my mind, I’m just one of those people who think it will never happen to me.

“If I could go back and have my time again I would never use sunbeds. I wouldn’t want to go through the stress and worry of having cancer for the sake of a tan.”

A survey of 4,000 people carried out last year found that one in three women has used a sunbed at some point, with 80% first using one when they were under the age of 35.

Caroline Cerny, campaign manager for Cancer Research UK’s SunSmart campaign, said: “Spending time on sunbeds is just as dangerous as staying out too long in sun.

“Sunbeds don’t offer a safe way to tan. The intensity of UV rays in some sunbeds can be more than 10 times stronger than the midday sun.

“Excessive exposure to UV damages the DNA in skin cells which increases the risk of skin cancer and makes skin age faster.

“But, importantly, if people take care not to burn in the sun and don’t use sunbeds, the majority of malignant melanoma could be prevented.”

According to the most recent figures, collected in 2005, around 50 women under the age of 40 in the UK die from melanoma each year, with deaths among all ages accounting for around 1,800 each year.

Genetic mutation ‘triggers most melanoma’

Washington, April 7 (ANI): A team of British scientists has identified a genetic mutation that may trigger up to 70 percent of cases of the most deadly form of skin cancer – melanoma.

Previous studies have shown that the BRAF gene was often damaged or mutated in melanomas – but it is not known whether this was a cause or result of the cancer.

The Institute of Cancer Research study shows that acquiring the mutation can be the first in a cascade of genetic changes leading to melanoma.

It confirms that BRAF is a driving force behind the disease and could be the trigger that causes melanoma.

“We know that excessive sun exposure is the main cause of skin cancer, but not much is known about the genetics behind it,” the BBC quoted lead author Professor Richard Marais, as saying.

“Our study shows that the genetic damage of BRAF is the first step in skin cancer development. Understanding this process will help us develop more effective treatments for the disease,” Marais added.

Over-exposure to sunlight causes at least two thirds of all malignant melanomas. This excessive exposure damages DNA and causes genetic mutations.

The study features in the journal Cancer Cell. (ANI)

Gene that suppresses skin cancer growth identified

London, March 30 (ANI): Scientists at the National Institutes of Health (NIH) in the U.S. have announced the discovery of a gene that suppresses tumour growth in melanoma, the deadliest form of skin cancer.

The finding was made as part of a systematic genetic analysis of a group of enzymes implicated in skin cancer, and many other types of cancer.

According to the analysis, one-quarter of human skin cancer tumours had mutations in genes that code for matrix metalloproteinase (MMP) enzymes.

The researchers believe that their findings may pave the way for more individualized cancer treatment strategies, where MMP and other key enzymes play a functional role in tumour growth and spread of the disease.

They even say that their study may help understand why drugs designed to treat cancer by blocking MMP enzymes have not been very successful as yet.

During the current study, the team led by researchers from the National Human Genome Research Institute (NHGRI) have found that MMP-8 actually serves as a tumour suppressor gene in melanoma, which is why may not be wise to block all MMPs in skin cancer patients with mutation in this gene.

The researchers say that a better approach may be to look for drugs that restore or increase MMP-8 function, or for drugs that block only those MMPs that are truly oncogenes-genes that encode proteins involved in normal cell growth.

“This research is an illustrative proof of concept that shows the value of genomic strategies for understanding cancer and possible therapies,” Nature magazine quoted Dr. Eric Green, NHGRI Scientific Director, as saying.

“It is gratifying to see that genomic technologies are guiding scientific discovery, advancing cancer research, especially melanoma research,” Green added.

While experimenting on mice, the researcher observed that when they injected the animals with cells expressing normal MMP-8, they would not develop skin ulcers.

However, when the mice were injected with cells expressing mutated MMP-8, they went on to develop ulcerations and metastases in their lungs.

A research article on the gene discovery has been published in the journal Nature Genetics. (ANI)